ArticleCanadian respiratory journal2026
Yifei Decoction Regulates the NGF/TRKA/PI3K/AKT Signaling Axis to Inhibit the Epithelial-Mesenchymal Transformation and Proliferation of Pulmonary Epithelial Cells in Bleomycin-Induced Pulmonary Fibrogenesis.
Article in Canadian respiratory journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: It was important to find better therapeutic drugs for idiopathic pulmonary fibrosis (IPF), and in our previous study, Yifei decoction (YFT) alleviated IPF. A deeper understanding of its mechanisms of action could aid in the development of novel treatment strategies. Methods: We established an IPF mouse model by administering bleomycin (BLM), followed by treatment with YFT. Histopathological analysis of lung tissue was conducted to evaluate the effects of YFT, along with transcriptomic profiling to identify key regulatory molecules involved in its therapeutic action. Immunofluorescence staining was performed for TRKA and surfactant protein C (SP-C) in IPF lung slices. A549 cells were induced with TGF-β1 to assess the effect of YFT on alveolar epithelial cells, and cells overexpressing TRKA were constructed. Western blotting analysis was performed to detect EMT- and PI3K/AKT pathway-related protein levels, and an EdU proliferation assay was conducted to measure the proliferation of A549 cells. Results: YFT intervention reduced pathological lung injury in BLM-treated mice. GO enrichment analysis revealed enrichment of DEGs in the extracellular matrix and proteinaceous extracellular matrix. Analysis of the enriched KEGG pathways revealed enrichment of the PI3K-AKT signaling pathway. YFT also decreased the number of SP-C Conclusion: YFT might regulate the NGF/TRKA/PI3K/AKT pathway to alleviate pulmonary fibrosis by reducing EMT and cell proliferation. This study laid the groundwork for future research on the possible enhancement of the therapeutic effect of YFT when YFT is combined with other medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.